Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2018
Decisions relating to the funded brands of some anti-retroviral treatments for HIV
20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in ...
Posted by Michael Wonder on 16 Oct 2018
Proposal to award sole supply and change some anti-retroviral brands
16 October 2018 - PHARMAC is seeking feedback on a proposal to make several changes to funding of anti-retroviral therapies ...
Posted by Michael Wonder on 09 Sep 2016
Proposal relating to two HIV treatments (Tivicay and Kivexa)
9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...
Posted by Michael Wonder on 02 Aug 2016
Decision regarding funding of pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
2 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe and Dohme (New Zealand) ...